UCB S.A.'s just-completed acquisition of Zogenix, Inc. already looked like a shrewd bit of business and the up-to-$1.9bn purchase is increasingly looking like a snip now that the epilepsy drug Fintepla has secured another approval in the US, this time for Lennox-Gastaut syndrome (LGS).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?